Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has been given a consensus rating of “Buy” by the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $48.50.

AAPG has been the topic of several recent research reports. Piper Sandler initiated coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 price target on the stock. BTIG Research initiated coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 target price on the stock. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Truist Financial set a $51.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, November 24th. Finally, Oppenheimer started coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They set an “outperform” rating and a $45.00 target price for the company.

Institutional Trading of Ascentage Pharma Group International

Institutional investors and hedge funds have recently modified their holdings of the stock. UBS Group AG grew its holdings in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period. XY Capital Ltd grew its holdings in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares during the period. Tema Etfs LLC bought a new stake in shares of Ascentage Pharma Group International in the 2nd quarter valued at $610,000. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the 2nd quarter valued at $391,000. Finally, Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the 3rd quarter worth $383,000.

Ascentage Pharma Group International Trading Up 2.3%

Shares of Ascentage Pharma Group International stock opened at $29.31 on Friday. The firm has a 50 day simple moving average of $32.49 and a 200 day simple moving average of $36.71. Ascentage Pharma Group International has a fifty-two week low of $16.50 and a fifty-two week high of $48.45. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.